Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Fuji Pharma Co Ltd Receives Marketing Authorization for Filgrastim


Wednesday, 21 Nov 2012 02:30am EST 

Fuji Pharma Co Ltd announced that it has received marketing authorization for filgrastim, which is co-developed by Fuji Pharma Co Ltd and Mochida Pharmaceutical Co Ltd. 

Latest Developments for Fuji Pharma Co Ltd

Company Quote

1956.0
29.0 +1.50%
24 Oct 2014